Similar Search Results

Tort reform : the case of medical malpractice

Danzon, Patricia Munch - In: Oxford review of economic policy 10 (1994) 1, pp. 84-98

Persistent link: https://www.econbiz.de/10001331908

Pharmaceutical pricing in emerging markets : effects of income, competition, and procurement

Danzon, Patricia Munch; Mulcahy, Andrew W.; Towse, Adrian K. - In: Health economics 24 (2015) 2, pp. 238-252

Persistent link: https://www.econbiz.de/10011317852

Mergers and acquisitions in the pharmaceutical and biotech industries

Danzon, Patricia Munch; Epstein, Andrew; Nicholson, Sean - 2004

Persistent link: https://www.econbiz.de/10002104576

Trade and price differentials for pharmaceuticals : policy options

Danzon, Patricia Munch - 1997

Persistent link: https://www.econbiz.de/10001583136

The Oxford handbook of the economics of the biopharmaceutical industry

Danzon, Patricia Munch (ed.); Nicholson, Sean (contributor) - 2012

Persistent link: https://www.econbiz.de/10009551494

The regulation of the pharmaceutical industry

Towse, Adrian; Danzon, Patricia Munch - In: The Oxford handbook of regulation, (pp. 548-571). 2010

Persistent link: https://www.econbiz.de/10009231027

Vaccine supply : effects of regulation and competition

Danzon, Patricia Munch; Pereira, Nuno Sousa - 2011

Persistent link: https://www.econbiz.de/10009234557

Effects of regulation on drug launch and pricing in interdependent markets

Danzon, Patricia Munch; Epstein, Andrew - In: The economics of medical technology, (pp. 35-71). 2012

Persistent link: https://www.econbiz.de/10010212756

Regulation of the pharmaceutical-biotechnology industry

Danzon, Patricia Munch; Keuffel, Eric L. - In: Economic regulation and its reform : what have we learned?, (pp. 407-484). 2014

Persistent link: https://www.econbiz.de/10010373334

Effects of regulation on drug launch and pricing in interdependent markets

Danzon, Patricia Munch; Epstein, Andrew J. - 2008

"This study examines the effect of price regulation and competition on launch timing and pricing of new drugs. Our data cover launch experience in 15 countries for drugs in 12 therapeutic classes that experienced significant innovation over the decade 1992-2003. We use prices of established...

Persistent link: https://www.econbiz.de/10003725066